LB Pharmaceuticals Inc
LBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001691082
No open-market purchases or sales by LB Pharmaceuticals Inc insiders were filed in the last 90 days; 114 institutions reported holding it in 13F filings for Q2 2026, worth $965.9M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding LB Pharmaceuticals Inc changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 68 | 2 | 77 | +11 |
| Shares | 24.8M | 1.13M | 28.2M | +4.55M (+19.2%) |
| Value | $551.8M | $25.2M | $692.4M | +$165.8M (+31.5%) |
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held LB Pharmaceuticals Inc at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Caligan Partners LP | 1,438,070 | $34.6M | 2.45% |
| Vanguard Capital Management LLC | 894,653 | $22.1M | 0.00% |
| Great Point Partners LLC | 300,000 | $7.40M | 1.81% |
| Vanguard Fiduciary Trust Co | 157,426 | $3.88M | 0.00% |
| Millennium Management LLC | 136,966 | $3.38M | 0.00% |
| Vanguard Portfolio Management LLC | 112,497 | $2.77M | 0.00% |
| Eversept Partners, LP | 100,198 | $2.47M | 0.16% |
| Janus Henderson Group PLC | 65,429 | $1.61M | 0.00% |
| Wellington Management Group LLP | 52,640 | $1.30M | 0.00% |
| StemPoint Capital LP | 50,000 | $1.23M | 0.24% |
| Calamos Advisors LLC | 24,063 | $593.4K | 0.00% |
| Meyer Handelman Co | 15,094 | $372.2K | 0.01% |
| Opaleye Management Inc. | 14,506 | $357.7K | 0.05% |
| Quadrature Capital Ltd | 9,931 | $244.9K | 0.00% |
| Vanguard Global Advisers, LLC | 8,753 | $215.8K | 0.00% |
| New York State Common Retirement Fund | 6,100 | $150.4K | 0.00% |
| The PNC Financial Services Group, Inc. | 145 | $3.58K | 0.00% |
| Massmutual Trust Co FSB | 54 | $1.33K | 0.00% |
| Allworth Financial LP | 1 | $25 | 0.00% |
| EverSource Wealth Advisors, LLC | 1 | $25 | 0.00% |
Sold out (9)
Institutions that held LB Pharmaceuticals Inc at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Longbow Finance SA | 82,336 | $1.83M |
| Jane Street Group, LLC | 31,733 | $706.4K |
| XTX Topco Ltd | 19,121 | $425.6K |
| Marshall Wace, LLP | 18,014 | $401.0K |
| Jefferies Financial Group Inc. | 12,445 | $277.0K |
| SG Americas Securities, LLC | 6,434 | $143.0K |
| Persistent Asset Partners Ltd | 4,080 | $90.8K |
| Royal Bank of Canada | 767 | $17.0K |
| Amalgamated Bank | 605 | $13.0K |
Not filed for Q1 2026 yet (2)
Institutions that held LB Pharmaceuticals Inc at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 1,112,978 | $24.8M |
| Norges Bank | 20,000 | $445.2K |